Novo Nordisk A/s

Other

Dgi Biotechnologies, Inc.

Per Hertz Hansen

Svend Havelund

Ib Jonassen

Peter Kurtzhals

Jan Markussen

Niels Christian Kaarsholm

Jakob Brandt

Neil I Goldstein

Arthur J Blume

Renee Brissette

Renuka Pillutla

John Halstro Slashedm

Lauge Schäffer

Søren Østergaard

Jane Spetzler

John B Halstrøm

James Beasley

Weiqing Cheng

Mark Ravera

Ku-Chuan Hsiao

Wlodek S Mandecki

Sören Östergaard

A pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.

Peptide derivatives

The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &#x3b1;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.

Insulin derivatives

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.

Insulin and IGF-1 receptor agonists and antagonists

The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.

The present invention relates to a pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.

Growing community of inventors

Lyngby, Denmark

Per Hertz Hansen